P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update
M.L. Johnson(Sarah Cannon), Neil H. Segal(Kettering University), Sandip Ganguly(Regeneron (United States)), S. Li(Regeneron (United States)), F. Seebach(Regeneron (United States)), Melissa Mathias(Regeneron (United States)), N.J. Lakhani(Van Andel Institute), Eugenia Girda(Rutgers, The State University of New Jersey), L. Fong(University of California, San Francisco), Alexandra Moesta(Regeneron (United States)), Davendra Sohal(University of Cincinnati), Yingying Hao(Harbin Medical University), Hee‐Sun Han(University of Illinois Urbana-Champaign), Anthony J. Olszanski(Fox Chase Cancer Center), Michael D. Kinnaman(Regeneron (United States))
Cited by 0
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484